Provided by Tiger Fintech (Singapore) Pte. Ltd.

NovoCure

20.18
+0.92004.78%
Post-market: 20.11-0.0700-0.35%19:43 EST
Volume:925.40K
Turnover:18.49M
Market Cap:2.22B
PE:-12.90
High:20.50
Open:19.39
Low:19.25
Close:19.26
Loading ...

Novocure: Positive Topline Results From Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields (Ttfields) Therapy for Pancreatic Cancer

THOMSON REUTERS
·
02 Dec 2024

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Reuters
·
02 Dec 2024

Novocure: Plans to File for Regulatory Approval in the U.S., EU, Japan and Other Key Markets

THOMSON REUTERS
·
02 Dec 2024

Novocure: Ttfields Therapy Was Well-Tolerated, Safety Was Consistent With Prior Clinical Studies

THOMSON REUTERS
·
02 Dec 2024

Novocure: Panova-3 Trial Met Primary Endpoint, Shows Significant Survival Improvement

THOMSON REUTERS
·
02 Dec 2024

Novocure Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Nov 2024

NovoCure’s Buy Rating Backed by FDA Approval and Strategic Growth Plans Amidst Potential Risks

TIPRANKS
·
21 Nov 2024

NovoCure Gets FDA Nod for Updated Optune Gio Arrays

MT Newswires Live
·
21 Nov 2024

Novocure announces FDA approval of new head flexible electrode transducer arrays

TIPRANKS
·
21 Nov 2024

BRIEF-FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Reuters
·
21 Nov 2024

FDA Approves Novocure’s Innovative Hfe Transducer Arrays for Use With Optune Gio® for Glioblastoma

THOMSON REUTERS
·
21 Nov 2024

Novocure Ltd - to Convert Optune Gio Users to New Hfe Arrays by Mid-2025

THOMSON REUTERS
·
21 Nov 2024

Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)

TIPRANKS
·
05 Nov 2024

Executive reshuffles: BIIB, USB and WES

seekingalpha
·
03 Nov 2024

Stock Track | NovoCure's Q3 2024 Results: Growth Amid Key Milestones and Strategic Transition

Stock Track
·
31 Oct 2024

NovoCure’s Strong Q3 and Leadership Changes in 2024

TipRanks
·
31 Oct 2024